View in EDS

A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.

Saved in:
Bibliographic Details
Title: A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Authors: Desroys du Roure P; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Lajoie L; Université de Tours - INRAE, UMR1282, Infectiologie et Santé Publique (ISP), équipe BioMédicaments Anti-Parasitaires (BioMAP), Tours, France., Mallavialle A; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Alcaraz LB; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Mansouri H; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.; RHEM, IRCM, Montpellier, France., Fenou L; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Garambois V; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Rubio L; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., David T; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Coenon L; IRMB, University of Montpellier, INSERM, CNRS, CHU Montpellier, Montpellier, France., Boissière-Michot F; Translational Research Unit, ICM, Montpellier, France., Chateau MC; Translational Research Unit, ICM, Montpellier, France., Ngo G; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Jarlier M; Biometry Department, ICM, Montpellier, France., Villalba M; IRMB, University of Montpellier, INSERM, CNRS, CHU Montpellier, Montpellier, France.; Institut du Cancer Avignon-Provence Sainte Catherine, Avignon, France., Martineau P; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Laurent-Matha V; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Roger P; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.; Department of Pathology, CHU Nîmes, Nimes, France., Guiu S; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.; Department of Medical Oncology, ICM, Montpellier, France., Chardès T; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.; CNRS, Centre national de la recherche Scientifique, Paris, F-75016, France., Gros L; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.; CNRS, Centre national de la recherche Scientifique, Paris, F-75016, France., Liaudet-Coopman E; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France emmanuelle.liaudet-coopman@inserm.fr.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jan 30; Vol. 12 (1). Date of Electronic Publication: 2024 Jan 30.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2023-007135